CL2019002953A1 - Anticuerpo anti-pd-l1 y uso del mismo. - Google Patents

Anticuerpo anti-pd-l1 y uso del mismo.

Info

Publication number
CL2019002953A1
CL2019002953A1 CL2019002953A CL2019002953A CL2019002953A1 CL 2019002953 A1 CL2019002953 A1 CL 2019002953A1 CL 2019002953 A CL2019002953 A CL 2019002953A CL 2019002953 A CL2019002953 A CL 2019002953A CL 2019002953 A1 CL2019002953 A1 CL 2019002953A1
Authority
CL
Chile
Prior art keywords
antibodies
fully human
affinity
human anti
ability
Prior art date
Application number
CL2019002953A
Other languages
English (en)
Inventor
Yan Lavrovsky
Ting Xu
Sergei Barbashov
Alexey Repik
Mikhail Samsonov
Vasily Ignatiev
Shorena Archuadze
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of CL2019002953A1 publication Critical patent/CL2019002953A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DAN A CONOCER ANTICUERPOS ANTI-PD-L1 COMPLETAMENTE HUMANOS Y SUS APLICACIONES CORRESPONDIENTES. LOS ANTICUERPOS COMPLETAMENTE HUMANOS TIENEN LA CAPACIDAD DE ENLAZARSE ESPECÍFICAMENTE A PD-L1 DE HUMANO. LOS ANTICUERPOS SE OBTUVIERON AL EMPLEAR UNA TÉCNICA DE PROSPECCIÓN BASADA EN UNA GENOTECA DE DESPLIEGUE EN LEVADURA Y TAMBIÉN POR MEDIO DE LA MADURACIÓN DE LA AFINIDAD PARA MEJORAR ADICIONALMENTE SU AFINIDAD POR PD-L1. LOS ANTICUERPOS ANTI-PD-L1 COMPLETAMENTE HUMANOS DADOS A CONOCER MUESTRAN BUENA ESPECIFICIDAD, AFINIDAD Y ESTABILIDAD. ÉSTOS TIENEN LA CAPACIDAD DE MEJORAR LA ACTIVIDAD DE CÉLULAS T AL ENLAZARSE A CÉLULAS T ACTIVADAS, MIENTRAS QUE INHIBEN SIGNIFICATIVAMENTE EL CRECIMIENTO DE TUMORES. LOS ANTICUERPOS ANTI-PD-L1 COMPLETAMENTE HUMANOS DADOS A CONOCER SE PUEDEN USAR EN EL DIAGNÓSTICO Y EL TRATAMIENTO DE CÁNCERES RELACIONADOS CON PD-L1 Y OTRAS ENFERMEDADES ASOCIADAS.
CL2019002953A 2017-04-18 2019-10-16 Anticuerpo anti-pd-l1 y uso del mismo. CL2019002953A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18

Publications (1)

Publication Number Publication Date
CL2019002953A1 true CL2019002953A1 (es) 2020-01-10

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002953A CL2019002953A1 (es) 2017-04-18 2019-10-16 Anticuerpo anti-pd-l1 y uso del mismo.

Country Status (16)

Country Link
US (1) US20210115143A1 (es)
EP (1) EP3612565A4 (es)
JP (2) JP2020517239A (es)
KR (1) KR102323960B1 (es)
CN (1) CN110856446A (es)
AU (1) AU2018256392B2 (es)
BR (1) BR112019021828B1 (es)
CA (1) CA3059447A1 (es)
CL (1) CL2019002953A1 (es)
CO (1) CO2019012118A2 (es)
EA (1) EA201900443A1 (es)
MA (1) MA50038A (es)
MX (1) MX2019012461A (es)
PH (1) PH12019502302A1 (es)
SG (1) SG11201909041SA (es)
WO (1) WO2018195226A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN113677709A (zh) * 2019-04-11 2021-11-19 斯克里普斯抗体研究所 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途
MX2021004897A (es) * 2019-04-26 2021-06-18 I Mab Biopharma Us Ltd Anticuerpos pd-l1 humano.
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
CA2926856A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
US10835595B2 (en) * 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
CA2940242A1 (en) * 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
US10336824B2 (en) * 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
RU2770590C2 (ru) * 2016-10-30 2022-04-18 Шанхай Хенлиус Байотек, Инк. Антитела против pd-l1 и их варианты

Also Published As

Publication number Publication date
WO2018195226A1 (en) 2018-10-25
AU2018256392B2 (en) 2024-05-16
MX2019012461A (es) 2019-12-11
CN110856446A (zh) 2020-02-28
PH12019502302A1 (en) 2020-09-21
MA50038A (fr) 2020-07-08
US20210115143A1 (en) 2021-04-22
KR102323960B1 (ko) 2021-11-10
BR112019021828A2 (pt) 2020-03-24
CA3059447A1 (en) 2018-10-25
EP3612565A4 (en) 2021-06-16
JP2023025003A (ja) 2023-02-21
EP3612565A1 (en) 2020-02-26
AU2018256392A1 (en) 2019-10-17
EA201900443A1 (ru) 2020-03-06
CO2019012118A2 (es) 2020-04-01
BR112019021828B1 (pt) 2022-09-20
JP2020517239A (ja) 2020-06-18
SG11201909041SA (en) 2019-11-28
KR20190141169A (ko) 2019-12-23

Similar Documents

Publication Publication Date Title
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
BR112018067458A2 (pt) anticorpos para tigit
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
CO2020000438A2 (es) Anticuerpos anti-ctla-4 y sus usos
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
EA201691487A1 (ru) Антитела человека к pd-l1
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
MX2017001599A (es) Anticuerpos novedosos y sus usos.
BR112017027254A2 (pt) anticorpos anti-cd123 e conjugados e derivados dos mesmos
EA202090204A1 (ru) Анти-cd137 антитела
CR20210197A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CL2011000117A1 (es) Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.
MX2020010946A (es) Anticuerpos multiespecificos y usos del mismo.
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CY1124456T1 (el) Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
EA201691836A1 (ru) Антитела к mcam и соответствующие способы их применения